iSERA Lifesciences has approved the notice for its 34th Annual General Meeting (AGM), scheduled for September 29, 2026. The board meeting held on September 1, 2026, also finalized the appointment of a scrutinizer for the event.

The company’s Board of Directors convened via video conferencing from 3:30 pm to 4:00 pm to consider these matters under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Approvals

The board approved the following items during the session:

• Notice for the 34th AGM to be held on Tuesday, September 29, 2026, at 3 pm (IST) through Video Conferencing or Other Audio-Visual Means (OAVM).
• Adoption of the audited standalone financial statements for the financial year ended March 31, 2026.
• Approval of the Annual Report for FY26, including the Director’s Report and its annexures.
• Appointment of M/s. Anuj Gupta & Associates as the Scrutinizer for remote e-voting and e-voting during the AGM.

iSERA Lifesciences submitted its monitoring agency report for the quarter ended June 30, 2026, to the Bombay Stock Exchange on August 14, 2026. The filing details the utilization of proceeds from its rights issue of equity shares, which raised an aggregate amount of ₹8.08 crore. Infometrics Valuation and Rating Limited served as the monitoring agency for the issue.

The company utilized ₹1.15 crore of the net proceeds during the first quarter of FY27. This expenditure was allocated across three primary heads: financing working capital requirements, general corporate purposes, and issue-related expenses. As of the end of the quarter, ₹6.26 crore remained unutilized.

Utilization Breakdown

The deployment of funds aligns with the objects specified in the letter of offer dated October 16, 2025. The statutory auditor, GMKS & Co Chartered Accountants, verified the details and confirmed no deviations from the disclosed expenditures.

Note: Issue-related expenses were incurred prior to this quarter or are yet to be fully booked in this period's utilization summary as per the report structure.

Working Capital and Corporate Expenses

The company directed ₹0.93 crore towards financing working capital requirements. These funds were used to meet operational and administrative expenses, supporting the company’s technology-enabled services model which involves longer receivable cycles. An additional ₹0.22 crore was deployed for general corporate purposes, specifically towards securing new office premises as outlined in the offer document.

Deployment of Unutilized Proceeds

The unutilized balance of ₹6.26 crore has been parked in fixed deposits and current accounts to preserve capital while awaiting further deployment. The majority of these funds are invested in fixed deposits with Kotak Mahindra Bank.

What the Numbers Show

The slow burn rate of the rights issue proceeds indicates a conservative approach to capital deployment in the immediate post-issue period. With only 14% of the total raised capital utilized in the first quarter, the company retains significant financial flexibility. The concentration of unutilized funds in short-term fixed deposits earning between 5.25% and 5.50% suggests a focus on liquidity preservation rather than immediate aggressive expansion or capex execution.

Regulatory Compliance

The filing was made pursuant to Regulation 82 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, read with Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The monitoring agency declared that there were no material deviations from the objects of the issue and no change in the means of finance. The Board of Directors approved the revised timeline for fund utilization via resolution dated April 22, 2026, citing strategic realignment and administrative lead times.